Shares of Corbus Pharmaceuticals are down about 5.7% in pre-market trading on Wednesday after reporting lower-than-expected 3Q results.
Corporate insiders – company officers, board members, and hedge fund managers – are known to be careful about how they allocate their funds. …
Cantor analyst Elemer Piros is out with a short brief on Corbus (NASDAQ:CRBP) shares after the drug maker reported 1Q18 financial results and provided an …
Cantor analyst Elemer Piros reiterated a Buy rating on shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) with a price target of $17, after the …
Investors in Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) should be smiling from ear to ear today after the drug maker announced positive topline results …
For those wondering why Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) shares are presently taking a 25% nosedive, look no further than The Street blogger …
